Tag: pharmaceuticals

  • SBIR Grant Awarded for Drug-to-Drug Interactions Research

    Optivia Biotechnology Inc. in Menlo Park, California received a $1.85 million Small Business Innovation Research (SBIR) grant from National Institutes of Health to determine the mechanisms that underlie certain drug-to-drug interactions, to help improve medication safety. The award was made by the National Institute of General Medical Sciences at NIH. The phase 2 SBIR grant…

  • Database to Track Substandard, Counterfeit Medicines

    U.S. Pharmacopeial Convention, a pharmaceutical industry standards body in Rockville, Maryland, unveiled its Medicines Quality Database (MQDB) that provides information on the quality of medicines in Africa, South America and Southeast Asia. The database, funded by the U.S. Agency for International Development, has more than 8,700 records of tested samples collected in Ghana, Laos, Vietnam,…

  • BARDA Contract Awarded for Antiviral Influenza Drug

    The U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded a contract to Biota Scientific Management Pty in Melbourne, Australia for an antiviral drug to combat influenza. The contract for advanced development and testing of the drug is valued at $231 million over five years. The drug, CS-8958, is a long-acting neuraminidase inhibitor, which prevents…

  • Merck to Offer Biotech Funding, Incubator in Israel

    The global pharmaceutical company Merck in Darmstadt, Germany has opened the Merck Serono Israel Bioincubator Fund, to support Israeli biotech and materials science start up companies. Merck’s chairman Karl-Ludwig Kley announced the initiative yesterday during meetings with officials in Israel. Merck’s incubator program covers pharmaceuticals, life sciences, and high-performance materials. The program will offer start…

  • Yale, Gilead Sciences to Collaborate on Cancer Therapies

    Gilead Sciences Inc., a biopharmaceutical company in Foster City, California and Yale School of Medicine in New Haven, Connecticut agreed on a multi-year research collaboration for the discovery of new cancer therapies. Gilead will have the first option to license Yale’s findings that result from the collaboration. The research effort will initially span four years…

  • FDA Approves Melanoma Immunotherapy Drug

    The U.S. Food and Drug Administration (FDA) approved Yervoy — ipilimumab — to treat patients with late-stage metastatic melanoma, a dangerous type of skin cancer. Yervoy is marketed by Bristol-Myers Squibb, in Princeton, New Jersey. Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in…

  • Potential Non-Insulin Type 1 Diabetes Treatment Discovered

    Researchers at University of Texas Southwestern Medical Center in Dallas and three other institutions have discovered a hormone pathway that could lead to new ways of treating type 1 diabetes. Results of this study appear in the March 25 issue of the journal Science (paid subscription required). Type 1 diabetes is usually diagnosed in children…

  • Organic Nanoparticle in Development for Cancer Drug Delivery

    A research team at Ontario Cancer Institute in Toronto, Canada have created an organic nanoparticle that they say can potentially change the way tumors are treated. Their findings appear online in the journal Nature Materials (paid subscription required). The researchers, led by the institute’s Gang Zheng (pictured left), say these new nanoscale particles — 1…

  • Clinical Trial Underway for Seasonal/H1N1 Vaccine

    Medicago Inc., a biotechnology company in Quebec City, Canada has begun a phase I clinical trial of its H1N1 influenza vaccine candidate in the United States. The trial tests the drug’s safety, tolerability, and capacity to induce an immune response, with results expected in three months. The randomized, double-blind, multicenter, active- and placebo-controlled dose-ranging study…

  • Drug in Development Targeting Nicotine Metabolism

    Research underway at the Academy of Finland in Helsinki is developing a new type of drug that could help smokers quit the habit. The new drug would slow down the metabolism of nicotine, which would help reduce the addictive power of their smoking. Nicotine is absorbed quickly through the lungs and the lining of the…